ClinicalTrials.gg
CompletedNCT06511076Updated Jan 6, 2026Results posted

A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult Participants

A Phase 1 interventional study of Zilucoplan in Healthy Volunteers, sponsored by UCB Biopharma SRL. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-06.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to assess the bioequivalence pharmacokinetics, safety, tolerability and device deficiencies of zilucoplan (ZLP) in healthy adult participants

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
03

In context

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive, at the time of signing the .
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants must be vaccinated with a quadrivalent vaccine and serogroup B vaccine against meningococcal infections (N. meningitidis) at least 2 weeks before the first administration of IMP if not previously vaccinated within 3 years prior to the start of IMP administration. Study participants who are not previously vaccinated may receive Menactra® (quadrivalent vaccine) and Bexsero® (serogroup B vaccine) during the Screening Period, 2 weeks prior to initiating IMP.
  • (BMI) ≥18.5 to ≤30.0kg/m2 at the Screening Visit.
  • Male and/or female:
  • A male participant must agree to use during the Treatment Period as detailed in Appendix 4 of the protocol and for at least 40 days (approximately 5 half lives) after the last dose of IMP and refrain from donating sperm during this period.
  • A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
  • Not a female/woman of (WOCBP) OR
  • A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 40 days (approximately 5 half lives), corresponding to time needed to eliminate IMP after the last dose of IMP.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of or current significant medical disorder, psychiatric disorder, or laboratory abnormality that in the opinion of the Investigator makes the study participant unsuitable for participation in the study, including any previous or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking IMP; or interfering with the interpretation of data.
  • Current or recent systemic infection within 2 weeks before the first administration of IMP or infection requiring intravenous antibiotics within 4 weeks before the first administration of IMP.
  • Current history of alcohol or drug use disorder, as defined in V, within the previous 6 months.
  • Participant has a known to any components of the IMP or comparative drugs (and/or an device) as stated in the protocol.
  • Intended use of over-the-counter or prescription medication, vitamins, herbal/traditional medicines (including St John's Wort) or dietary supplements (excluding medicines for external use), with the exception of those specified in the Protocol, within 2 weeks before the first administration of IMP.
  • Participant has used hepatic enzyme-inducing drugs (eg, , phenobarbital, isoniazid, phenytoin, rifampicin) within 2 months before the first administration of IMP.
  • Participant has previously participated in this study or participant has previously been assigned to treatment in a study of the medication under investigation in this study.
  • Participant has participated in another study of an IMP (and/or an investigational device) within the previous 30 days or 5 half-lives (whichever is longer), or is currently participating in another study of an IMP (and/or an investigational device).
  • Participants with abnormalities in a standard 12-lead (ECG) at the Screening Visit as judged by the Investigator.
  • Presence of surface antigen at the Screening Visit or within 3 months prior to dosing.
  • Positive antibody test result at the Screening Visit or within 3 months prior to starting IMP. NOTE: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled if a confirmatory negative hepatitis C ribonucleic acid (RNA) test is obtained.
  • Positive hepatitis C RNA test result at the Screening Visit or within 3 months prior to first dose of IMP. NOTE: Test is optional and participants with negative hepatitis C antibody test are not required to also undergo hepatitis C RNA testing.
  • Positive antibody test at the Screening Visit.
  • Positive syphilis test at the Screening Visit.
  • Positive throat swab for N. meningitidis at the Screening Visit or a prior history of meningitis.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Treatment Sequence AB

    Study participants randomized to this arm will receive a single subcutaneous (sc) injection of zilucoplan using pre-filled syringe (ZLP-PFS; Treatment A) as reference and a single sc injection of zilucoplan using an autoinjector (ZLP-AI; Treatment B) as test in the treatment sequence A-B on Day 1 of each Treatment Period.

    Drug: Zilucoplan

  • Experimental
    Treatment Sequence BA

    Study participants randomized to this arm will receive a single sc injection of zilucoplan using pre-filled syringe (ZLP-PFS; Treatment A) as reference and a single sc injection of zilucoplan using an autoinjector (ZLP-AI; Treatment B) as test in the treatment sequence B-A on Day 1 of each Treatment Period.

    Drug: Zilucoplan

Interventions

  • Participants will receive a single sc injection of zilucoplan in the pre-specified sequence.

    Also known as: RA101495

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero (Predose [Day 1]) to Infinity (AUC) for Zilucoplan

    AUC was defined as the area under the plasma concentration-time curve from time zero (predose \[Day 1\]) to infinity for zilucoplan.

    Time frame: Baseline (Day 1 of each treatment period at predose) and at predefined time points up to 816 hours (Day 35) postdose

  2. Area Under the Plasma Concentration-time Curve From Time 0 (Predose [Day 1]) to the Time of the Last Quantifiable Concentration (AUC[0-t]) for Zilucoplan

    AUC(0-t) was defined as the area under the plasma concentration-time curve from time 0 (predose \[Day 1\]) to the time of the last quantifiable concentration for zilucoplan.

    Time frame: Baseline (Day 1 of each treatment period at predose) and at predefined time points up to 816 hours (Day 35) postdose

  3. Maximum Observed Plasma Concentration (Cmax) for Zilucoplan

    Cmax was defined as the maximum observed plasma concentration for zilucoplan.

    Time frame: Baseline (Day 1 of each treatment period at predose) and at predefined time points up to 816 hours (Day 35) postdose

Secondary outcomes

  1. Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

    An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product, whether or not considered related to the investigational medicinal product. A TEAE was defined as any AE with a start date/time on or after the administration of IMP in each Treatment Period, and up to and including 40 days after the single dose in each Treatment Period (or up to the first dose in Period 2 (for TEAEs following the first dose in Period 1) or last contact date (for TEAEs following the first dose in Period 2) depending on which occurs first. Percentages were displayed to one decimal place and was correspond to whole participant counts due to rounding.

    Time frame: From Day 1 to EOS visit or ET visit (up to 82 days)

  2. Percentage of Participants With Serious Treatment-emergent Adverse Events (Serious TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

    An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Important medical events such as (but not limited to) invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, convulsions not resulting in hospitalization, or development of intervention dependency or intervention abuse.

    Time frame: From Day 1 to EOS visit or ET visit (up to 82 days)

  3. Percentage of Participants With Serious Adverse Device Effects (SADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

    An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Important medical events such as (but not limited to) invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, convulsions not resulting in hospitalization, or development of intervention dependency or intervention abuse. A SADE was defined as an adverse device effect that has resulted in any of the consequences characteristic of a SAE.

    Time frame: From Day 1 to EOS visit or ET visit (up to 82 days)

  4. Percentage of Participants With Non-serious Adverse Device Effects (ADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

    An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical device. An ADE was defined as an AE related to the use of an investigational medical device.

    Time frame: From Day 1 to EOS visit or ET visit (up to 82 days)

07

Results

Posted Jan 6, 2026

Participant flow

The study started to enroll participants in August 2024 and concluded in November 2024.

Treatment Period 1 (35 Days)
Participant flow — Treatment Period 1 (35 Days)
MilestoneSequence: Treatment A (ZLP-PFS) - Treatment B (ZLP-AI)Sequence: Treatment B (ZLP-AI) - Treatment A (ZLP-PFS)
Started77
Completed77
Not completed00
Treatment Period 2 (35 Days)
Participant flow — Treatment Period 2 (35 Days)
MilestoneSequence: Treatment A (ZLP-PFS) - Treatment B (ZLP-AI)Sequence: Treatment B (ZLP-AI) - Treatment A (ZLP-PFS)
Started77
Completed77
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time Zero (Predose [Day 1]) to Infinity (AUC) for Zilucoplan

AUC was defined as the area under the plasma concentration-time curve from time zero (predose \[Day 1\]) to infinity for zilucoplan.

Time frame:
Baseline (Day 1 of each treatment period at predose) and at predefined time points up to 816 hours (Day 35) postdose
Reported as:
Geometric mean · hour*nanogram per milliliters (h*ng/mL)
Area Under the Plasma Concentration-time Curve From Time Zero (Predose [Day 1]) to Infinity (AUC) for Zilucoplan
hour*nanogram per milliliters (h*ng/mL)ZLP-PFSZLP-AI
Area Under the Plasma Concentration-time Curve From Time Zero (Predose [Day 1]) to Infinity (AUC) for Zilucoplan950930 ± 15.0932740 ± 17.1
Statistical analysis
  • ZLP-PFS vs ZLP-AI · Mixed Effects model · Glsm ratio: 0.9809 · 90% CI 0.9529 to 1.0097The GLSM ratio was calculated: ZLP-AI/ZLP-PFS
PrimaryArea Under the Plasma Concentration-time Curve From Time 0 (Predose [Day 1]) to the Time of the Last Quantifiable Concentration (AUC[0-t]) for Zilucoplan

AUC(0-t) was defined as the area under the plasma concentration-time curve from time 0 (predose \[Day 1\]) to the time of the last quantifiable concentration for zilucoplan.

Time frame:
Baseline (Day 1 of each treatment period at predose) and at predefined time points up to 816 hours (Day 35) postdose
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time 0 (Predose [Day 1]) to the Time of the Last Quantifiable Concentration (AUC[0-t]) for Zilucoplan
h*ng/mLZLP-PFSZLP-AI
Area Under the Plasma Concentration-time Curve From Time 0 (Predose [Day 1]) to the Time of the Last Quantifiable Concentration (AUC[0-t]) for Zilucoplan921190 ± 14.5904500 ± 16.4
Statistical analysis
  • ZLP-PFS vs ZLP-AI · Mixed Effects model · Glsm ratio: 0.9819 · 90% CI 0.9543 to 1.0102The GLSM ratio was calculated: ZLP-AI/ZLP-PFS
PrimaryMaximum Observed Plasma Concentration (Cmax) for Zilucoplan

Cmax was defined as the maximum observed plasma concentration for zilucoplan.

Time frame:
Baseline (Day 1 of each treatment period at predose) and at predefined time points up to 816 hours (Day 35) postdose
Reported as:
Geometric mean · nanograms per milliliters (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for Zilucoplan
nanograms per milliliters (ng/mL)ZLP-PFSZLP-AI
Maximum Observed Plasma Concentration (Cmax) for Zilucoplan5599.8 ± 11.35597.6 ± 11.0
Statistical analysis
  • ZLP-PFS vs ZLP-AI · Mixed Effects model · Glsm ratio: 0.9996 · 90% CI 0.9594 to 1.0416The GLSM ratio was calculated: ZLP-AI/ZLP-PFS
SecondaryPercentage of Participants With Treatment-emergent Adverse Events (TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product, whether or not considered related to the investigational medicinal product. A TEAE was defined as any AE with a start date/time on or after the administration of IMP in each Treatment Period, and up to and including 40 days after the single dose in each Treatment Period (or up to the first dose in Period 2 (for TEAEs following the first dose in Period 1) or last contact date (for TEAEs following the first dose in Period 2) depending on which occurs first. Percentages were displayed to one decimal place and was correspond to whole participant counts due to rounding.

Time frame:
From Day 1 to EOS visit or ET visit (up to 82 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit
percentage of participantsZLP-PFSZLP-AI
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit57.157.1
SecondaryPercentage of Participants With Serious Treatment-emergent Adverse Events (Serious TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Important medical events such as (but not limited to) invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, convulsions not resulting in hospitalization, or development of intervention dependency or intervention abuse.

Time frame:
From Day 1 to EOS visit or ET visit (up to 82 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Treatment-emergent Adverse Events (Serious TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit
percentage of participantsZLP-PFSZLP-AI
Percentage of Participants With Serious Treatment-emergent Adverse Events (Serious TEAEs) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit00
SecondaryPercentage of Participants With Serious Adverse Device Effects (SADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

An SAE was defined as any untoward medical occurrence that, at any dose, met 1 or more of the criteria listed: * Results in death * Is life-threatening * Requires inpatient hospitalization or prolongation of existing hospitalization * Results in persistent or significant disability/incapacity * Is a congenital anomaly/birth defect * Important medical events such as (but not limited to) invasive or malignant cancers, intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias, convulsions not resulting in hospitalization, or development of intervention dependency or intervention abuse. A SADE was defined as an adverse device effect that has resulted in any of the consequences characteristic of a SAE.

Time frame:
From Day 1 to EOS visit or ET visit (up to 82 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Serious Adverse Device Effects (SADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit
percentage of participantsZLP-PFSZLP-AI
Percentage of Participants With Serious Adverse Device Effects (SADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit00
SecondaryPercentage of Participants With Non-serious Adverse Device Effects (ADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit

An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory finding) in study participants, users, or other persons, whether or not related to the investigational medical device. An ADE was defined as an AE related to the use of an investigational medical device.

Time frame:
From Day 1 to EOS visit or ET visit (up to 82 days)
Reported as:
Number · percentage of participants
Percentage of Participants With Non-serious Adverse Device Effects (ADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit
percentage of participantsZLP-PFSZLP-AI
Percentage of Participants With Non-serious Adverse Device Effects (ADE) From Day 1 up to the End of Study (EOS) Visit or Early Termination (ET) Visit00

Adverse events

Collected over From Day 1 to EOS visit or ET visit (up to 82 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ZLP-PFS0/14 (0%)0/14 (0%)8/14 (57.1%)
ZLP-AI0/14 (0%)0/14 (0%)8/14 (57.1%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventZLP-PFSZLP-AI
NasopharyngitisInfections and infestations3/145/14
HeadacheNervous system disorders2/142/14
Gingival bleedingGastrointestinal disorders0/141/14
NauseaGastrointestinal disorders0/141/14
Abdominal painGastrointestinal disorders1/140/14
Abdominal pain lowerGastrointestinal disorders1/140/14
Aphthous ulcerGastrointestinal disorders1/140/14
Gastrooesophageal reflux diseaseGastrointestinal disorders1/140/14
Vessel puncture site bruiseGeneral disorders0/141/14
Catheter site papuleGeneral disorders1/140/14

Baseline characteristics

Baseline refers All Randomized Study Participants which consisted of all study participants who were randomized.

Age, Continuous
Age, Continuous(years)Sequence: Treatment A (ZLP-PFS) - Treatment B (ZLP-AI)Sequence: Treatment B (ZLP-AI) - Treatment A (ZLP-PFS)Total
Mean29.0 ± 5.936.1 ± 15.930.8 ± 10.0
Age, Customized
Age, Customized(Participants)Sequence: Treatment A (ZLP-PFS) - Treatment B (ZLP-AI)Sequence: Treatment B (ZLP-AI) - Treatment A (ZLP-PFS)Total
18 - <65 years7714
65 - <85 years000
>=85 years000
Sex: Female, Male
Sex: Female, Male(Participants)Sequence: Treatment A (ZLP-PFS) - Treatment B (ZLP-AI)Sequence: Treatment B (ZLP-AI) - Treatment A (ZLP-PFS)Total
Female4610
Male314
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence: Treatment A (ZLP-PFS) - Treatment B (ZLP-AI)Sequence: Treatment B (ZLP-AI) - Treatment A (ZLP-PFS)Total
Asian101
White5712
Other or Mixed101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Sequence: Treatment A (ZLP-PFS) - Treatment B (ZLP-AI)Sequence: Treatment B (ZLP-AI) - Treatment A (ZLP-PFS)Total
Not Hispanic or Latino7714
08

Study locations

1 site
  • DV0012 1
    Groningen, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Due to the small sample size in this trial, individual patient-level data cannot be adequately anonymized as there is a reasonable likelihood that individual participants could be re-identified. For this reason, data from this trial cannot be shared.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2024 to primary completion in Nov 2024, 3 months.

Results were first posted in Jan 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2024
First posted
Jul 19, 2024
StartActual
Aug 5, 2024
Primary completionActual
Nov 26, 2024
CompletionActual
Nov 26, 2024
Results first posted
Jan 6, 2026
Last update
Jan 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06511076
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Jul 19, 2024
Start date
Aug 5, 2024
Primary completion
Nov 26, 2024
Completion
Nov 26, 2024
Results posted
Jan 6, 2026
Last update
Jan 6, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion